Continuous Glucose Monitoring Market to Grow at a Robust CAGR of 22% Through 2031 | North America Leads Adoption, Asia Pacific Fastest-Growing | Key Players - Abbott, Dexcom, Medtronic, Senseonics

Leander, Texas and Tokyo, Japan - Feb.3.2026
As per DataM Intelligence research report "Global Continuous Glucose Monitoring by DataM Intelligence estimates the market to grow at a CAGR of 22% from 2024 to 2031."

The market is driven by rising diabetes prevalence, increasing awareness of preventive care, technological advancements in sensors for real-time monitoring across age groups, integration with insulin pumps, and supportive government initiatives for glycemic control. New product launches enhance accuracy, reduce hypoglycemia risks, and support home healthcare. Despite challenges like device accuracy inconsistencies, frequent calibration needs, and limited reimbursement coverage, demand surges with FDA approvals for over-the-counter CGMs and shift to outpatient settings.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/continuous-glucose-monitoring-market?sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Continuous Glucose Monitoring Market: Competitive Intelligence
Abbott Laboratories, Dexcom, Inc., Medtronic Plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, A. Menarini Diagnostics s.r.l, Johnson & Johnson, GlySens Incorporated, Echo Therapeutics, Inc., Medtrum Technologies, Inc.

The Continuous Glucose Monitoring Market continues to gain structural strength through the combined influence of Abbott Laboratories, Dexcom, Inc., Medtronic Plc, Senseonics Holdings, Inc., F. Hoffmann-La Roche Ltd, A. Menarini Diagnostics s.r.l, Johnson & Johnson, GlySens Incorporated, Echo Therapeutics, Inc., and Medtrum Technologies, Inc. Together, these companies support critical diabetes management in home care, hospitals, and clinics, where real-time accuracy, longevity, alerts for hypo/hyperglycemia, and integration with automated insulin delivery (AID) systems remain essential. Their portfolios address demanding requirements including extended wear times (up to 365 days), minimal calibration, and compatibility with apps/smart devices across Type 1, Type 2, and prediabetes patients. As a result, the Continuous Glucose Monitoring Market benefits from steady demand, rapid innovation in implantable/wearable tech, and broad relevance despite reimbursement and accuracy hurdles.

The collective momentum created by these companies enhances the competitive depth of the Continuous Glucose Monitoring Market by combining global scale with specialized R&D in biosensors and AI analytics. Abbott Laboratories, Dexcom, Inc., and Medtronic Plc bring extensive manufacturing, FDA-cleared iCGM systems, and partnerships for AID interoperability that reinforce market leadership. At the same time, Senseonics Holdings, Inc., GlySens Incorporated, and A. Menarini Diagnostics s.r.l contribute long-term implantable solutions and OTC innovations, particularly for non-insulin users and wellness applications. This balance of scale, longevity tech, and geographic reach supports consistent availability and adaptation to evolving diabetes care protocols and patient-centric needs.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/continuous-glucose-monitoring-market?sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Fund Raisings
✅ Q1 2025 - Senseonics Holdings, Inc. (United States)
Senseonics raised $16M in a Registered Direct Offering to support Eversense 365 commercialization and next-gen CGM development.
✅ Q1 2025 - Senseonics Holdings, Inc. (United States)
Senseonics raised additional $27M via ATM Sales, repaying 2025 notes to strengthen balance sheet for EU launch and pipeline advancement.

Product Launches & Partnerships
✅ September 2025 - Dexcom, Inc. (United States)
Dexcom launched G7 15-Day CGM sensor for adults, offering extended wear, higher accuracy, and seamless AID integration with Tandem, Omnipod, and iLet systems.
✅ September 2025 - Abbott Laboratories & Medtronic Plc (United States)
Abbott and Medtronic partnered to launch Instinct sensor (FreeStyle Libre-based) for MiniMed 780G pumps, enabling cross-company automated insulin delivery with 75% time-in-range improvement.
✅ April 2025 - Senseonics Holdings, Inc. & Sequel Med Tech (United States)
Senseonics partnered with Sequel Med Tech for twiist AID pump integration with Eversense 365, creating first 1-year closed-loop CGM-pump solution launching 2H 2025.

Segment Covered in the Continuous Glucose Monitoring
Market:
By Component
The market is segmented into Sensors (fastest-growing due to glucose oxidase tech and accuracy improvements ~40-50% share), Transmitters, Receivers, Insulin Pumps Integration, Others, with sensors dominating for real-time interstitial fluid monitoring.
By End-User
End-users include Home Healthcare (leading ~50% with convenience and OTC shift), Hospitals/ICUs, Diagnostics Centers, driven by remote monitoring and reduced clinician burden.
By Application
Applications cover Type 1 Diabetes (dominant), Type 2 Diabetes, Prediabetes/Wellness (growing with OTC CGMs), with integration for all ages enhancing glycemic balance and HbA1c reduction.

Buy Now & Unlock 360° Market Intelligence:
https://www.datamintelligence.com/buy-now-page?report=continuous-glucose-monitoring-market&sindhuri
(Single User Report: USD 4350 & One Year Database Subscription: USD 12K)

Regional Analysis
North America - Largest Share (~45%)
North America leads with the largest share due to high diabetes prevalence (e.g., 11M Canadians with diabetes/prediabetes), FDA approvals for OTC/iCGM, key players like Abbott/Dexcom/Medtronic, and strong reimbursement/insurance coverage in the U.S./Canada.
Europe - ~25% Share
Europe holds a significant share supported by regulatory approvals (e.g., CE Mark for Eversense 365), NHS adoption, and demand in Germany, UK, Italy for advanced AID-integrated CGMs.
Asia Pacific - Fastest-Growing (~30% Share)
Asia Pacific is fastest-growing driven by diabetes surge in China/India/Japan, government initiatives, rising middle-class adoption, and local innovations like Dexcom expansions.
Latin America - ~5% Share
Latin America accounts for emerging growth with urbanization and improving access in Brazil/Mexico.
Middle East & Africa - 5% Share
Middle East & Africa expands via infrastructure investments and rising awareness in GCC/South Africa.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sindhuri
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.